Distinct neurolinguistic symptom clusters in Alzheimer's-type dementia and primary progressive aphasia

Chris Westbury1, Dan Bub, Howie Chertkow

  • 1Department of Psychology, University of Alberta, Edmonton, Canada. chrisw@pop.srv.ualberta.ca

Brain and Cognition
|May 28, 2002
PubMed

Insights

Primary Progressive Aphasia (PPA) is a syndrome of progressive language decline. This study differentiates PPA from dementia of Alzheimer's type (DAT) by analyzing linguistic deficits in 11 PPA and 11 DAT patients.

Area of Science:

  • Neuroscience
  • Linguistics
  • Neurology

Background:

  • Primary Progressive Aphasia (PPA) was first described by Mesulam in 1982 as a syndrome of slowly progressive aphasia without dementia.
  • Existing literature on PPA is unsystematic and incomplete, hindering theoretical framework development.
  • Distinguishing PPA from dementia of Alzheimer's type (DAT) is challenging due to overlapping early symptoms.

Purpose of the Study:

  • To analyze and contrast the linguistic deficits in patients with PPA and DAT.
  • To identify linguistic symptom clusters that differentiate PPA from DAT.
  • To provide a more coherent theoretical framework for understanding PPA.

Main Methods:

  • Analysis of linguistic deficits in 11 PPA patients and 11 DAT patients.
  • Utilized the extensive Psycholinguistic Assessment of Language Battery (PALB) for patient testing.
  • Examined seven specific linguistic symptom clusters for group differentiation.

Main Results:

  • Identified seven distinct linguistic symptom clusters differentiating PPA from DAT.
  • Detailed analysis revealed specific patterns of language deficits in each group.
  • The findings contribute to a clearer distinction between these neurodegenerative conditions.

Conclusions:

  • Linguistic deficit analysis provides a robust method for differentiating PPA from DAT.
  • The identified symptom clusters offer valuable diagnostic markers.
  • Further research can build upon these findings to refine understanding and diagnosis of PPA.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes loosely...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...